147 related articles for article (PubMed ID: 11481288)
1. The inhibition and selectivity of bacterial topoisomerases by BMS-284756 and its analogues.
Lawrence LE; Wu P; Fan L; Gouveia KE; Card A; Casperson M; Denbleyker K; Barrett JF
J Antimicrob Chemother; 2001 Aug; 48(2):195-201. PubMed ID: 11481288
[TBL] [Abstract][Full Text] [Related]
2. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.
Yague G; Morris JE; Pan XS; Gould KA; Fisher LM
Antimicrob Agents Chemother; 2002 Feb; 46(2):413-9. PubMed ID: 11796351
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of action of the des-F(6) quinolone BMS-284756 measured by supercoiling inhibition and cleavable complex assays.
Wu P; Lawrence LE; Denbleyker KL; Barrett JF
Antimicrob Agents Chemother; 2001 Dec; 45(12):3660-2. PubMed ID: 11709365
[TBL] [Abstract][Full Text] [Related]
4. Bactericidal activities of BMS-284756, a novel Des-F(6)-quinolone, against Staphylococcus aureus strains with topoisomerase mutations.
Lawrence LE; Frosco M; Ryan B; Chaniewski S; Yang H; Hooper DC; Barrett JF
Antimicrob Agents Chemother; 2002 Jan; 46(1):191-5. PubMed ID: 11751133
[TBL] [Abstract][Full Text] [Related]
5. Selection and genetic characterization of Streptococcus pneumoniae mutants resistant to the des-F(6) quinolone BMS-284756.
Hartman-Neumann S; DenBleyker K; Pelosi LA; Lawrence LE; Barrett JF; Dougherty TJ
Antimicrob Agents Chemother; 2001 Oct; 45(10):2865-70. PubMed ID: 11557482
[TBL] [Abstract][Full Text] [Related]
6. Activity of non-fluorinated quinolones (NFQs) against quinolone-resistant Escherichia coli and Streptococcus pneumoniae.
Roychoudhury S; Twinem TL; Makin KM; McIntosh EJ; Ledoussal B; Catrenich CE
J Antimicrob Chemother; 2001 Jul; 48(1):29-36. PubMed ID: 11418510
[TBL] [Abstract][Full Text] [Related]
7. Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.
Pestova E; Millichap JJ; Noskin GA; Peterson LR
J Antimicrob Chemother; 2000 May; 45(5):583-90. PubMed ID: 10797078
[TBL] [Abstract][Full Text] [Related]
8. The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus.
Schedletzky H; Wiedemann B; Heisig P
J Antimicrob Chemother; 1999 May; 43 Suppl B():31-7. PubMed ID: 10382873
[TBL] [Abstract][Full Text] [Related]
9. Action of quinolones against Staphylococcus aureus topoisomerase IV: basis for DNA cleavage enhancement.
Anderson VE; Zaniewski RP; Kaczmarek FS; Gootz TD; Osheroff N
Biochemistry; 2000 Mar; 39(10):2726-32. PubMed ID: 10704224
[TBL] [Abstract][Full Text] [Related]
10. Contribution of the 8-methoxy group to the activity of gatifloxacin against type II topoisomerases of Streptococcus pneumoniae.
Kishii R; Takei M; Fukuda H; Hayashi K; Hosaka M
Antimicrob Agents Chemother; 2003 Jan; 47(1):77-81. PubMed ID: 12499172
[TBL] [Abstract][Full Text] [Related]
11. The in vitro activity of BMS-284756, a new des-fluorinated quinolone.
Weller TM; Andrews JM; Jevons G; Wise R
J Antimicrob Chemother; 2002 Jan; 49(1):177-84. PubMed ID: 11751785
[TBL] [Abstract][Full Text] [Related]
12. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance.
Akasaka T; Tanaka M; Yamaguchi A; Sato K
Antimicrob Agents Chemother; 2001 Aug; 45(8):2263-8. PubMed ID: 11451683
[TBL] [Abstract][Full Text] [Related]
13. In-vitro activity of moxifloxacin against fluoroquinolone-resistant strains of aerobic gram-negative bacilli and Enterococcus faecalis.
Tankovic J; Bachoual R; Ouabdesselam S; Boudjadja A; Soussy CJ
J Antimicrob Chemother; 1999 May; 43 Suppl B():19-23. PubMed ID: 10382871
[TBL] [Abstract][Full Text] [Related]
14. Correlation of in vitro susceptibilities to newer quinolones of naturally occurring quinolone-resistant Neisseria gonorrhoeae strains with changes in GyrA and ParC.
Shultz TR; Tapsall JW; White PA
Antimicrob Agents Chemother; 2001 Mar; 45(3):734-8. PubMed ID: 11181352
[TBL] [Abstract][Full Text] [Related]
15. Activity of BMS-284756, a novel des-fluoro(6) quinolone, against Staphylococcus aureus, including contributions of mutations to quinolone resistance.
Low DE; Muller M; Duncan CL; Willey BM; de Azavedo JC; McGeer A; Kreiswirth BN; Pong-Porter S; Bast DJ
Antimicrob Agents Chemother; 2002 Apr; 46(4):1119-21. PubMed ID: 11897603
[TBL] [Abstract][Full Text] [Related]
16. Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae.
Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Nishino Y; Ishihara S; Kawada Y
J Antimicrob Chemother; 1997 Oct; 40(4):543-9. PubMed ID: 9372424
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, antibacterial activity, and toxicity of 7-(isoindolin-5-yl)-4-oxoquinoline-3-carboxylic acids. Discovery of the novel des-F(6)-quinolone antibacterial agent garenoxacin (T-3811 or BMS-284756).
Hayashi K; Takahata M; Kawamura Y; Todo Y
Arzneimittelforschung; 2002; 52(12):903-13. PubMed ID: 12572531
[TBL] [Abstract][Full Text] [Related]
18. Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones.
Strahilevitz J; Robicsek A; Hooper DC
Antimicrob Agents Chemother; 2006 Feb; 50(2):600-6. PubMed ID: 16436716
[TBL] [Abstract][Full Text] [Related]
19. Fluoroquinolones inhibit preferentially Streptococcus pneumoniae DNA topoisomerase IV than DNA gyrase native proteins.
Fernandez-Moreira E; Balas D; Gonzalez I; de la Campa AG
Microb Drug Resist; 2000; 6(4):259-67. PubMed ID: 11272253
[TBL] [Abstract][Full Text] [Related]
20. Purification of pneumococcal type II topoisomerases and inhibition by gemifloxacin and other quinolones.
Morrissey I; George JT
J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():101-6. PubMed ID: 10824040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
